First half of 2022 now completeS&P 500 down 21.08%.
Russell 2000 down 24.84%
NASDAQ down 30.34%.
S&P Biotech ETF down 35.66%
CZO down only 3.28%.
Truly an exceptional performance in what has been the worst market for biotech ever and the worst start of the year for the S&P 500 in 32 years. CZO has proven a store of value in very difficult times. Next up the opportunity defining pipeline data, etc.